Guess which ASX AI stock rocketed 170% on an AstraZeneca update

Investors are loving this company's announcement on Wednesday.

| More on:
A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

LBT Innovations Limited (ASX: LBT) shares are catching the eye on Wednesday.

At one stage today, the ASX AI healthcare stock was up as much as 170% to 3.8 cents.

The medical technology company's shares have given back most of these gains since then but remains up 80% to 2.5 cents.

Why is this ASX AI healthcare stock rocketing?

Investors were scrambling to buy the company's shares today after it announced the successful completion of primary validation for the Automated Plate Assessment System (APAS) PharmaQC product.

The company's APAS product uses artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates.

The completion of this milestone represents the final step in the product development and technology commercialisation with global healthcare giant AstraZeneca (NASDAQ: AZN).

As a result, AstraZeneca will now undertake an internal secondary validation of the system within its own manufacturing processes. Completion of AstraZeneca's secondary validation is anticipated in the third quarter of calendar year 2024.

If that is successful, then it could be only a matter of time until the ASX AI healthcare stock is generating revenue.

'Incredibly important'

The company's CEO and managing director, Brent Barnes, was very pleased with the news and believes the technology is important to the industry. He said:

Evidence based automation is incredibly important in the biopharmaceutical industry. The completion of our primary validation is a valuable asset to the Company. We expect this data to build confidence in our technology and assist customers with their adoption of APAS PharmaQC.

Many customers we've spoken to over the past 6 months gave positive feedback on our technological approach and we are looking forward to sharing our primary validation data with them. We have set ourselves an ambitious commercialisation schedule for 2024 and expect the customer qualification pipeline to accelerate as we present our APAS PharmaQC technology at a number of key global conferences.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended AstraZeneca Plc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Will CSL shares rise in value over the next 12 months? Here's what the experts say

Can CSL have a better year in FY2025?

Read more »

ANZ ASX 200 banks capital return Group of investors madly grabbing for cash on city street.
Healthcare Shares

ResMed shares rebounding as investors rush to buy the dip

ResMed is rising as ASX investors buy the dip following yesterday's 13% share price dive.

Read more »

A fit man flexes his muscles, indicating a positive share price movement on the ASX market
ETFs

How to invest in US weight loss drug stocks on the ASX

Want to buy shares in the maker of Ozempic? There's an ASX ETF for that.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

ResMed share price plunges 13% as weight-loss results reawaken worries

Why are investors heading to the exits today? Let's see what's happening.

Read more »

Exhausted young Caucasian woman lying on comfortable sofa in living room sleeping after hard-working day, tired millennial female fall asleep on couch at home, take nap or daydream, fatigue concept
Healthcare Shares

ResMed shares are in a two-month lull. Is this a chance to buy?

ResMed shares are still trading below the price targets of several brokers.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Healthcare Shares

Botanix shares jump on FDA approval and $70m capital raising

Investors are responding positively to some very big news.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Botanix Pharmaceuticals share price on watch amid FDA news and 'transformative event'

Big news has just been announced from this clinical dermatology company.

Read more »